Trial · NCT02443103
Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis
NCT02443103, Not applicable, Terminated, Kathy Miller; results first posted 2018-02-13
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis. Trials, record NCT02443103. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02443103
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis
- NCT number
- NCT02443103
- Status
- Terminated
- Phases
- Not applicable
- Enrollment
- 4 participants, actual
- Lead sponsor
- Kathy Miller
- Conditions
- Bone Cancer, Metastasis
- Interventions
- Guanabenz acetate
- First posted
- 2015-05-13
- Last updated
- 2018-02-13
- Results first posted
- 2018-02-13
- Limitations and caveats
- Due to poor accrual and the early closure, results were not obtained for the bone marker and pharmacokinetics analysis.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Bone Turnover Markers-bone Formation and Bone Resorption | Day 0, Week 8, Week 12 | Number of patients who had blood specimens taken to collect and evaluate markers of bone formation and bone resorption. Note - due to poor accrual and early closure, bone marker data was not collected. |
| Secondary | Treatment Related Adverse Events | Up to 1 year | Number of unique patients who had a treatment related (possible, probable or definite) adverse events. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Bone Turnover Markers-bone Formation and Bone Resorption | Day 0, Week 8, Week 12 | All patients receiving at least one dose of study drug and having at least one evaluable post-baseline visit with bone marker information available. | ||
| SECONDARY | Treatment Related Adverse Events | Up to 1 year | All patients enrolled and received treatment. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Treatment Related Adverse Events | Guanabenz | 2 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Guanabenz | 4 | |
| Overall Study | COMPLETED | Guanabenz | 1 | |
| Overall Study | NOT COMPLETED | Guanabenz | 3 |
Source ClinicalTrials.gov
Adverse events10
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Dyspepsia | Gastrointestinal disorders | Guanabenz | 2 | 4 | |
| other | Nausea | Gastrointestinal disorders | Guanabenz | 1 | 4 | |
| other | Vomiting | Gastrointestinal disorders | Guanabenz | 1 | 4 | |
| other | Fatigue | General disorders | Guanabenz | 1 | 4 | |
| other | Pain | General disorders | Guanabenz | 1 | 4 | |
| other | Dizziness | Nervous system disorders | Guanabenz | 1 | 4 | |
| other | Confusion | Psychiatric disorders | Guanabenz | 1 | 4 | |
| other | Insomnia | Psychiatric disorders | Guanabenz | 2 | 4 | |
| other | Hot flashes | Vascular disorders | Guanabenz | 1 | 4 | |
| other | Hypotension | Vascular disorders | Guanabenz | 1 | 4 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Guanabenz | ||
| Total, other adverse events | Guanabenz | 4 | 4 |
| Total, serious adverse events | Guanabenz | 0 | 4 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02443103
GET https://conductscience.org/api/trials/v1/NCT02443103/registered